A stock sentiment todayAgilent Technologies Inc
Sentiment verdict
Gossip first, financials second — NEUTRAL at 78% confidence.
Last updated · cached analysis, refreshes periodically
A
Agilent Technologies IncAgilent is a high-quality compounder navigating a cyclical trough in life sciences instrumentation, offering stability but lacking immediate growth catalysts.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for A. Not financial advice.
Price · last 12 months
Gossip
The prevailing narrative is one of 'cautious recovery.' Investors are monitoring a slowdown in biopharma spending and a sluggish recovery in the Chinese market, which historically serves as a major growth engine for Agilent's chromatography and mass spectrometry tools.
- ·Inventory destocking cycles
- ·Softness in China capital expenditures
- ·Expectations for interest rate cuts to revive lab spending
- ·Resilience in PFAS (forever chemicals) environmental testing demand
Financial
Agilent maintains a stellar balance sheet with industry-leading margins. While top-line growth has stalled recently, their high proportion of recurring revenue (consumables/services) provides a protective floor during hardware downturns.
- ·Operating Margins consistently above 25%
- ·Forward P/E of ~26x, slightly above historical averages
- ·Strong Free Cash Flow generation
- ·Net Debt/EBITDA remains comfortably under 2.0x
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Insiders sold a net $217K on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Continued budgetary constraints in early-stage biotech
- ·Geopolitical exposure to Chinese manufacturing and demand
- ·Stiff competition in the high-end mass spectrometry market
Peer temperature
How direct competitors stack up against A right now.
- HOTTMOThermo Fisher Scientific Inc.
HOTTER — larger scale and more diversified clinical trial services provide a more resilient moat against instrument sales volatility.
See full analysis → - COLDWATWaters Corporation
COLDER — higher concentration in the pharmaceutical sector makes it more vulnerable to the current spending lull than Agilent's diversified end-markets.
See full analysis → - HOTDHRDanaher Corporation
HOTTER — following the Veralto spin-off, it is a pure-play bioprocessing powerhouse with faster long-term secular growth tailwinds.
See full analysis →
- A-1.3%
- TMO+0.6%
- WAT-2.2%
- DHR-2.0%
Analyst price target
Consensus average of 19 analysts · median 175.00
Source: StockAnalysis.com · updated 2026-09-09
AI-generated analysis for informational purposes only. Not financial advice.